Multiscale Modeling in the Clinic: Drug Design and Development

Authored by Gary An, Jing Su, Xiaobo Zhou, Paolo Vicini, Colleen E Clancy, William R Cannon, Yaling Liu, Elebeoba E May, Peter Ortoleva, Aleksander S Popel, James P Sluka, David M Eckmann

Date Published: 2016

DOI: 10.1007/s10439-016-1563-0

Sponsors: United States Environmental Protection Agency (EPA) United States National Institutes of Health (NIH)

Platforms: No platforms listed

Model Documentation: Other Narrative

Model Code URLs: Model code not found

Abstract

A wide range of length and time scales are relevant to pharmacology, especially in drug development, drug design and drug delivery. Therefore, multiscale computational modeling and simulation methods and paradigms that advance the linkage of phenomena occurring at these multiple scales have become increasingly important. Multiscale approaches present in silico opportunities to advance laboratory research to bedside clinical applications in pharmaceuticals research. This is achievable through the capability of modeling to reveal phenomena occurring across multiple spatial and temporal scales, which are not otherwise readily accessible to experimentation. The resultant models, when validated, are capable of making testable predictions to guide drug design and delivery. In this review we describe the goals, methods, and opportunities of multiscale modeling in drug design and development. We demonstrate the impact of multiple scales of modeling in this field. We indicate the common mathematical and computational techniques employed for multiscale modeling approaches used in pharmacometric and systems pharmacology models in drug development and present several examples illustrating the current state-of-the-art models for (1) excitable systems and applications in cardiac disease; (2) stem cell driven complex biosystems; (3) nanoparticle delivery, with applications to angiogenesis and cancer therapy; (4) host-pathogen interactions and their use in metabolic disorders, inflammation and sepsis; and (5) computer-aided design of nanomedical systems. We conclude with a focus on barriers to successful clinical translation of drug development, drug design and drug delivery multiscale models.

Tags

Agent-based model computational model Mycobacterium-tuberculosis Systems chemical biology Virus-like particles Arrhythmogenic mechanisms Electrical restitution Molecular-dynamics Sicilian gambit Blood-vessels